A Survey of the Anti-apoptotic Bcl-2 Subfamily Expression in Cancer Types Provides a Platform to Predict the Efficacy of Bcl-2 Antagonists in Cancer Therapy

Overview

Journal Cell Death Dis

Specialties Cell Biology
General Medicine

Date 2011 Mar 3

PMID 21364647

Citations 155

Authors

W J Placzek

J Wei

S Kitada

D Zhai

J C Reed

M Pellecchia

Affiliations

Soon will be listed here.

Abstract

We investigated the mRNA expression levels of all six antiapoptotic Bcl-2 subfamily members in 68 human cancer cell lines using qPCR techniques and measured the ability of known Bcl-2 inhibitors to induce cell death in 36 of the studied tumor cell lines. Our study reveals that Mcl-1 represents the anti-apoptotic Bcl-2 subfamily member with the highest mRNA levels in the lung, prostate, breast, ovarian, renal, and glioma cancer cell lines. In leukemia/lymphoma and melanoma cancer cell lines, Bcl-2 and Bfl-1 had the highest levels of mRNA, respectively. The observed correlation between the cell killing properties of known Bcl-2 inhibitors and the relative mRNA expression levels of anti-apoptotic Bcl-2 proteins provide critical insights into apoptosis-based anticancer strategies that target Bcl-2 proteins. Our data may explain current challenges of selective Bcl-2 inhibitors in the clinic, given that severe expression of Bcl-2 seems to be limited to leukemia cell lines. Furthermore, our data suggest that in most cancer types a strategy targeted to Mcl-1 inhibition, or combination of Bfl-1 and Mcl-1 inhibition for melanoma, may prove to be more successful than therapies targeting only Bcl-2.

Citing Articles

Inducing apoptosis in acute myeloid leukemia; mechanisms and limitations.

Koolivand Z, Bahreini F, Rayzan E, Rezaei N Heliyon. 2025; 11(1):e41355.

PMID: 39811307 PMC: 11730532. DOI: 10.1016/j.heliyon.2024.e41355.

Overcoming Cancer Resistance: Strategies and Modalities for Effective Treatment.

Koirala M, DiPaola M Biomedicines. 2024; 12(8).

PMID: 39200265 PMC: 11351918. DOI: 10.3390/biomedicines12081801.

Discovery of a Myeloid Cell Leukemia 1 (Mcl-1) Inhibitor That Demonstrates Potent Activities in Mouse Models of Hematological and Solid Tumors.

Tarr J, Salovich J, Aichinger M, Jeon K, Veerasamy N, Sensintaffar J J Med Chem. 2024; 67(16):14370-14393.

PMID: 39102508 PMC: 11345828. DOI: 10.1021/acs.jmedchem.4c01188.

USP36 inhibits apoptosis by deubiquitinating cIAP1 and survivin in colorectal cancer cells.

Gao B, Qiao Y, Zhu S, Yang N, Zou S, Liu Y J Biol Chem. 2024; 300(7):107463.

PMID: 38876304 PMC: 11268115. DOI: 10.1016/j.jbc.2024.107463.

Effective Targeting of Melanoma Cells by Combination of Mcl-1 and Bcl-2/Bcl-x/Bcl-w Inhibitors.

Peng Z, Gillissen B, Richter A, Sinnberg T, Schlaak M, Eberle J Int J Mol Sci. 2024; 25(6).

PMID: 38542429 PMC: 10970841. DOI: 10.3390/ijms25063453.

References

Akgul C . Mcl-1 is a potential therapeutic target in multiple types of cancer. Cell Mol Life Sci. 2008; 66(8):1326-36. PMC: 11131550. DOI: 10.1007/s00018-008-8637-6. View

Wei J, Kitada S, Rega M, Emdadi A, Yuan H, Cellitti J . Apogossypol derivatives as antagonists of antiapoptotic Bcl-2 family proteins. Mol Cancer Ther. 2009; 8(4):904-13. PMC: 2750823. DOI: 10.1158/1535-7163.MCT-08-1050. View

Ding Q, He X, Xia W, Hsu J, Chen C, Li L . Myeloid cell leukemia-1 inversely correlates with glycogen synthase kinase-3beta activity and associates with poor prognosis in human breast cancer. Cancer Res. 2007; 67(10):4564-71. DOI: 10.1158/0008-5472.CAN-06-1788. View

Backus H, Riel J, Van Groeningen C, Vos W, Dukers D, Bloemena E . Rb, mcl-1 and p53 expression correlate with clinical outcome in patients with liver metastases from colorectal cancer. Ann Oncol. 2001; 12(6):779-85. DOI: 10.1023/a:1011112227044. View

Boisvert-Adamo K, Longmate W, Abel E, Aplin A . Mcl-1 is required for melanoma cell resistance to anoikis. Mol Cancer Res. 2009; 7(4):549-56. PMC: 2689141. DOI: 10.1158/1541-7786.MCR-08-0358. View

Fesik S . Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer. 2005; 5(11):876-85. DOI: 10.1038/nrc1736. View

Maruyama R, Yamana K, Itoi T, Hara N, Bilim V, Nishiyama T . Absence of Bcl-2 and Fas/CD95/APO-1 predicts the response to immunotherapy in metastatic renal cell carcinoma. Br J Cancer. 2006; 95(9):1244-9. PMC: 2360577. DOI: 10.1038/sj.bjc.6603359. View

Wolter K, Verhaegen M, Fernandez Y, Nikolovska-Coleska Z, Riblett M, de la Vega C . Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins. Cell Death Differ. 2007; 14(9):1605-16. DOI: 10.1038/sj.cdd.4402163. View

Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo P, Kitada S . Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006; 10(5):375-88. DOI: 10.1016/j.ccr.2006.10.006. View

10.

Green D, Kroemer G . The pathophysiology of mitochondrial cell death. Science. 2004; 305(5684):626-9. DOI: 10.1126/science.1099320. View

11.

Liang H, Fesik S . Three-dimensional structures of proteins involved in programmed cell death. J Mol Biol. 1998; 274(3):291-302. DOI: 10.1006/jmbi.1997.1415. View

12.

Zapata J, Krajewska M, Krajewski S, Huang R, Takayama S, Wang H . Expression of multiple apoptosis-regulatory genes in human breast cancer cell lines and primary tumors. Breast Cancer Res Treat. 1998; 47(2):129-40. DOI: 10.1023/a:1005940832123. View

13.

Oltersdorf T, Elmore S, Shoemaker A, Armstrong R, Augeri D, Belli B . An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005; 435(7042):677-81. DOI: 10.1038/nature03579. View

14.

Adams J, Cory S . The Bcl-2 protein family: arbiters of cell survival. Science. 1998; 281(5381):1322-6. DOI: 10.1126/science.281.5381.1322. View

15.

Chen S, Dai Y, Harada H, Dent P, Grant S . Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res. 2007; 67(2):782-91. DOI: 10.1158/0008-5472.CAN-06-3964. View

16.

Reed J . Dysregulation of apoptosis in cancer. J Clin Oncol. 1999; 17(9):2941-53. DOI: 10.1200/JCO.1999.17.9.2941. View

17.

Selzer E, Okamoto I, Pehamberger H, Potter R, Jansen B . Expression of Bcl-2 family members in human melanocytes, in melanoma metastases and in melanoma cell lines. Melanoma Res. 1998; 8(3):197-203. DOI: 10.1097/00008390-199806000-00001. View

18.

Zhai D, Jin C, Satterthwait A, Reed J . Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins. Cell Death Differ. 2006; 13(8):1419-21. DOI: 10.1038/sj.cdd.4401937. View

19.

Wang C, Guttridge D, Mayo M, Baldwin Jr A . NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol. 1999; 19(9):5923-9. PMC: 84448. DOI: 10.1128/MCB.19.9.5923. View

20.

Martin B, Paesmans M, Berghmans T, Branle F, Ghisdal L, Mascaux C . Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer. 2003; 89(1):55-64. PMC: 2394216. DOI: 10.1038/sj.bjc.6601095. View